Conmed (CNMD) EBIT Margin (2010 - 2026)

Conmed has reported EBIT Margin for 17 years, with the latest figure at 8.02% in Q1 2026.

• For the quarter ending Q1 2026, EBIT Margin rose 305.0% year-over-year to 8.02%; the trailing twelve-month figure through Mar 2026 stood at 8.18% (down 560.0% YoY), and the FY2025 full-year result was 7.46%, down 786.0% from the prior year.
• EBIT Margin for Q1 2026 stood at 8.02%, down from 9.81% in the prior quarter.
• The five-year high for EBIT Margin was 20.75% in Q3 2024, with the low at 0.44% in Q4 2022.
• Historically, EBIT Margin has averaged 9.62% across 5 years, with a median of 9.26% in 2022.
• Annual changes were most pronounced in 2023 — EBIT Margin surged 1578 bps — and 2025, when it plunged 1723 bps.
• Conmed's EBIT Margin stood at 0.44% in 2022, then jumped by 3616 bps to 15.35% in 2023, then dropped by 1 bps to 15.18% in 2024, then plunged by 35 bps to 9.81% in 2025, then retreated by 18 bps to 8.02% in 2026.
• The last three EBIT Margin figures came in at 8.02% (Q1 2026), 9.81% (Q4 2025), and 3.52% (Q3 2025), per Business Quant data.